Petra Mjehović
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Petra Mjehović has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Davor Miličić
University of Zagreb School of Medicine Department of Cardiovascular Diseases, University Hospital Centre Zagreb Zagreb
14 shared publications - Dora Fabijanović
Department of Biology, School of Medicine, University of Zagreb, Zagreb, Croatia
12 shared publications - Maja Čikeš
Department of Cardiovascular Diseases, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia
12 shared publications - Nina Jakuš
University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia
11 shared publications - Marijan Pašalić
Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
9 shared publications - Boško Skorić
University Hospital Centre Zagreb (UHC Zagreb)
8 shared publications
Latest Publications
- 1 September 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (11-12) , 298-289
Pregnancy in a heart transplant recipient with history of severe humoral and cellular rejection and positive donor-specific antibodies – case report
- 1 September 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (11-12) , 298-289
Pregnancy in a heart transplant recipient with history of severe humoral and cellular rejection and positive donor-specific antibodies – case report
- 1 September 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (11-12) , 297
Lower platelet count following induction therapy with anti-thymocyte globulin is associated with a lower incidence of cardiac allograft vasculopathy
- 1 September 2023
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 18 (11-12) , 297
Lower platelet count following induction therapy with anti-thymocyte globulin is associated with a lower incidence of cardiac allograft vasculopathy
- Open Access
- 18 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (14) , e028939
Relationship Between Azithromycin and Cardiovascular Outcomes in Unvaccinated Patients With COVID‐19 and Preexisting Cardiovascular Disease
Background: Empiric antimicrobial therapy with azithromycin is highly used in patients admitted to the hospital with COVID‐19, despite prior research suggesting that azithromycin may be associated with increased risk of cardiovascular events. Methods and Results: This study was conducted using data from the ISACS‐COVID‐19 (International Survey of Acute Coronavirus Syndromes‐COVID‐19) registry. Patients with a confirmed diagnosis of SARS‐CoV‐2 infection were eligible for inclusion. The study included 793 patients exposed to azithromycin within 24 hours from hospital admission and 2141 patients who received only standard care. The primary exposure was cardiovascular disease (CVD). Main outcome measures were 30‐day mortality and acute heart failure (AHF). Among 2934 patients, 1066 (36.4%) had preexisting CVD. A total of 617 (21.0%) died, and 253 (8.6%) had AHF. Azithromycin therapy was consistently associated with an increased risk of AHF in patients with preexisting CVD (risk ratio [RR], 1.48 [95% CI, 1.06–2.06]). Receiving azithromycin versus standard care was not significantly associated with death (RR, 0.94 [95% CI, 0.69–1.28]). By contrast, we found significantly reduced odds of death (RR, 0.57 [95% CI, 0.42–0.79]) and no significant increase in AHF (RR, 1.23 [95% CI, 0.75–2.04]) in patients without prior CVD. The relative risks of death from the 2 subgroups were significantly different from each other ( P interaction =0.01). Statistically significant association was observed between AHF and death (odds ratio, 2.28 [95% CI, 1.34–3.90]). Conclusions: These findings suggest that azithromycin use in patients with COVID‐19 and prior history of CVD is significantly associated with an increased risk of AHF and all‐cause 30‐day mortality. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05188612.
- 18 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (14) , e028939
Open AccessRelationship Between Azithromycin and Cardiovascular Outcomes in Unvaccinated Patients With COVID‐19 and Preexisting Cardiovascular Disease
Background: Empiric antimicrobial therapy with azithromycin is highly used in patients admitted to the hospital with COVID‐19, despite prior research suggesting that azithromycin may be associated with increased risk of cardiovascular events. Methods and Results: This study was conducted using data from the ISACS‐COVID‐19 (International Survey of Acute Coronavirus Syndromes‐COVID‐19) registry. Patients with a confirmed diagnosis of SARS‐CoV‐2 infection were eligible for inclusion. The study included 793 patients exposed to azithromycin within 24 hours from hospital admission and 2141 patients who received only standard care. The primary exposure was cardiovascular disease (CVD). Main outcome measures were 30‐day mortality and acute heart failure (AHF). Among 2934 patients, 1066 (36.4%) had preexisting CVD. A total of 617 (21.0%) died, and 253 (8.6%) had AHF. Azithromycin therapy was consistently associated with an increased risk of AHF in patients with preexisting CVD (risk ratio [RR], 1.48 [95% CI, 1.06–2.06]). Receiving azithromycin versus standard care was not significantly associated with death (RR, 0.94 [95% CI, 0.69–1.28]). By contrast, we found significantly reduced odds of death (RR, 0.57 [95% CI, 0.42–0.79]) and no significant increase in AHF (RR, 1.23 [95% CI, 0.75–2.04]) in patients without prior CVD. The relative risks of death from the 2 subgroups were significantly different from each other ( P interaction =0.01). Statistically significant association was observed between AHF and death (odds ratio, 2.28 [95% CI, 1.34–3.90]). Conclusions: These findings suggest that azithromycin use in patients with COVID‐19 and prior history of CVD is significantly associated with an increased risk of AHF and all‐cause 30‐day mortality. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05188612.
- Open Access
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 193
Clinically suspected post-transplantation myocarditis – a case series
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 193
Open AccessClinically suspected post-transplantation myocarditis – a case series
- Open Access
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 191-192
The effect of anticoagulation therapy on perioperative bleeding risk in patients undergoing heart transplantation
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 191-192
Open AccessThe effect of anticoagulation therapy on perioperative bleeding risk in patients undergoing heart transplantation
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 187-188
Desensitization procedures in heart transplant recipients: a case series
- 1 November 2022
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 17 (9-10) , 187-188
Desensitization procedures in heart transplant recipients: a case series
- Open Access
- 3 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
COVID-19 and acute heart failure among patients with cancer
Background: Patients with cancer represent a uniquely vulnerable population not only with higher susceptibility to COVID-19 but also at increased risk for death. However, detailed information on causes of death and the contribution of pre-existing health conditions to death yet is missing. Purpose: This study focuses on the implications of COVID-19 in the cardiovascular health of patients with cancer by assessing the relation between cancer and de novo acute heart failure (AHF) with in-hospital mortality. Methods: The initial population consisted of 3968 patients included in the ISACS COVID-19 registry between March 2020 and February 2022. Of these, 546 patients with chronic HF were excluded, leaving a final population of 3422. Patients were divided in two groups according to the presence or absence of a cancer diagnosis at the time of hospitalization for COVID-19. Primary outcomes were incidence of in-hospital mortality or AHF during hospitalization. Association between cancer and outcomes was estimated using multivariable logistic regression analyses. Subsidiary analysis was conducted to evaluate differences between patients with prior vs active cancer. Results: Of the 3422 patients included in the study, 468 patients had cancer (8.2% active, 5.5% past cancer). Cancer patients were older (68.9±13.4 vs 63.3±15.6, p-value <0.001) and more likely to be female (50.4% vs 39.1%, p-value <0.001). They presented more frequently with a history of chronic obstructive pulmonary disease (12.3% vs 7.6%, p-value = 0.001). When considering outcomes, cancer patients had a significantly higher incidence of in-hospital mortality (27.7% vs 19.2%; p-value <0.001). This despite the presence of a numerically higher mean PiO2/FiO2 (281±108.8 vs 267.05±122.5, p-value = 0.11) on admission and a lower rate of X-ray findings of interstitial pneumonia (60% vs 70.5%, p-value <0.001) than their non-oncological counterparts, as well as similar use of mechanical ventilation (30.6% vs 35.0%, p value=0.14). The association between cancer and death persisted when adjusting for demographic, laboratory findings and in-hospital treatment (OR: 1.46; 95% CI: 1.11–1.94; p value=0.01). Cancer patients also had higher rates of AHF (9.6% vs 4.7%, p-value <0.001) during hospitalization. This association was independent from presence of cardiovascular risk factors or comorbidities (OR: 1.61; 95% CI: 1.07–2.43; p value=0.02). When restricting the analysis to the cancer population, AHF appeared to be significantly associated with death (OR: 2.41; 95% CI 1.18–4.95; p-value = 0.01), but this correlation persisted only in patients affected by active cancer in age and sex adjusted analyses (OR: 4.27; 95% CI: 1.51–12.07; p value=0.01 vs 1.20; 95% CI: 0.38–3.76; p-value = 0.75). Conclusions: The incidence of AHF in cancer patients with COVID-19 is high. Patients with active cancer are also at high risk for mortality. This has implications for cardiac monitoring and chemotherapy administration during COVID-19. Funding Acknowledgement: Type of funding sources: None.
- 3 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessCOVID-19 and acute heart failure among patients with cancer
Background: Patients with cancer represent a uniquely vulnerable population not only with higher susceptibility to COVID-19 but also at increased risk for death. However, detailed information on causes of death and the contribution of pre-existing health conditions to death yet is missing. Purpose: This study focuses on the implications of COVID-19 in the cardiovascular health of patients with cancer by assessing the relation between cancer and de novo acute heart failure (AHF) with in-hospital mortality. Methods: The initial population consisted of 3968 patients included in the ISACS COVID-19 registry between March 2020 and February 2022. Of these, 546 patients with chronic HF were excluded, leaving a final population of 3422. Patients were divided in two groups according to the presence or absence of a cancer diagnosis at the time of hospitalization for COVID-19. Primary outcomes were incidence of in-hospital mortality or AHF during hospitalization. Association between cancer and outcomes was estimated using multivariable logistic regression analyses. Subsidiary analysis was conducted to evaluate differences between patients with prior vs active cancer. Results: Of the 3422 patients included in the study, 468 patients had cancer (8.2% active, 5.5% past cancer). Cancer patients were older (68.9±13.4 vs 63.3±15.6, p-value <0.001) and more likely to be female (50.4% vs 39.1%, p-value <0.001). They presented more frequently with a history of chronic obstructive pulmonary disease (12.3% vs 7.6%, p-value = 0.001). When considering outcomes, cancer patients had a significantly higher incidence of in-hospital mortality (27.7% vs 19.2%; p-value <0.001). This despite the presence of a numerically higher mean PiO2/FiO2 (281±108.8 vs 267.05±122.5, p-value = 0.11) on admission and a lower rate of X-ray findings of interstitial pneumonia (60% vs 70.5%, p-value <0.001) than their non-oncological counterparts, as well as similar use of mechanical ventilation (30.6% vs 35.0%, p value=0.14). The association between cancer and death persisted when adjusting for demographic, laboratory findings and in-hospital treatment (OR: 1.46; 95% CI: 1.11–1.94; p value=0.01). Cancer patients also had higher rates of AHF (9.6% vs 4.7%, p-value <0.001) during hospitalization. This association was independent from presence of cardiovascular risk factors or comorbidities (OR: 1.61; 95% CI: 1.07–2.43; p value=0.02). When restricting the analysis to the cancer population, AHF appeared to be significantly associated with death (OR: 2.41; 95% CI 1.18–4.95; p-value = 0.01), but this correlation persisted only in patients affected by active cancer in age and sex adjusted analyses (OR: 4.27; 95% CI: 1.51–12.07; p value=0.01 vs 1.20; 95% CI: 0.38–3.76; p-value = 0.75). Conclusions: The incidence of AHF in cancer patients with COVID-19 is high. Patients with active cancer are also at high risk for mortality. This has implications for cardiac monitoring and chemotherapy administration during COVID-19. Funding Acknowledgement: Type of funding sources: None.
- 1 January 2021
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 16 (1-2) , 42
Congenital coronary artery fistulas as a cause of angina pectoris
- 1 January 2021
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 16 (1-2) , 42
Congenital coronary artery fistulas as a cause of angina pectoris
- 1 January 2021
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 16 (1-2) , 25-26
COVID-19 in heart transplant recipients
- 1 January 2021
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 16 (1-2) , 25-26
COVID-19 in heart transplant recipients
- 1 October 2019
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 14 (9-10) , 211-212
Characteristics of patients with acute ST-segment elevation myocardial infarction treated with different combinations of antiaggregation therapy: experience from the Croatian branch of the ISACS-CT Registry
- 1 October 2019
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 14 (9-10) , 211-212
Characteristics of patients with acute ST-segment elevation myocardial infarction treated with different combinations of antiaggregation therapy: experience from the Croatian branch of the ISACS-CT Registry